The Utilization of Low Dose Naltrexone for Chronic Pain
© 2023. The Author(s), under exclusive licence to Springer Nature Switzerland AG..
Naltrexone is a mu-opioid receptor antagonist with a long half-life compared with naloxone. Both of these drugs, along with others, were developed with the intention of reversing the effects of opioid abuse or toxicity. Evidence has also shown that naltrexone has a benefit in preventing relapse by reducing opioid cravings and reducing symptoms of opioid withdrawal. The benefits of this drug were not only shown with opioid abuse. In 1984 this drug was also approved for alcohol abuse. Naltrexone has been proven to decrease alcohol relapse by decreasing the craving. Apart from these approved indications for the use of naltrexone, with time, it has been seen that this drug has a benefit in treating chronic pain. A number of studies have shown the benefits of this drug with inflammatory bowel disease, fibromyalgia, multiple sclerosis, diabetic neuropathy, and complex regional pain syndrome, among others. More studies are needed to approve this medication for specific chronic pain conditions.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:37 |
|---|---|
| Enthalten in: |
CNS drugs - 37(2023), 8 vom: 28. Aug., Seite 663-670 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Poliwoda, Salomon [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
5S6W795CQM |
|---|
| Anmerkungen: |
Date Completed 21.08.2023 Date Revised 21.09.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1007/s40263-023-01018-3 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM360053238 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM360053238 | ||
| 003 | DE-627 | ||
| 005 | 20231226082206.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s40263-023-01018-3 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1200.xml |
| 035 | |a (DE-627)NLM360053238 | ||
| 035 | |a (NLM)37505425 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Poliwoda, Salomon |e verfasserin |4 aut | |
| 245 | 1 | 4 | |a The Utilization of Low Dose Naltrexone for Chronic Pain |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 21.08.2023 | ||
| 500 | |a Date Revised 21.09.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2023. The Author(s), under exclusive licence to Springer Nature Switzerland AG. | ||
| 520 | |a Naltrexone is a mu-opioid receptor antagonist with a long half-life compared with naloxone. Both of these drugs, along with others, were developed with the intention of reversing the effects of opioid abuse or toxicity. Evidence has also shown that naltrexone has a benefit in preventing relapse by reducing opioid cravings and reducing symptoms of opioid withdrawal. The benefits of this drug were not only shown with opioid abuse. In 1984 this drug was also approved for alcohol abuse. Naltrexone has been proven to decrease alcohol relapse by decreasing the craving. Apart from these approved indications for the use of naltrexone, with time, it has been seen that this drug has a benefit in treating chronic pain. A number of studies have shown the benefits of this drug with inflammatory bowel disease, fibromyalgia, multiple sclerosis, diabetic neuropathy, and complex regional pain syndrome, among others. More studies are needed to approve this medication for specific chronic pain conditions | ||
| 650 | 4 | |a Journal Article | |
| 650 | 7 | |a Naltrexone |2 NLM | |
| 650 | 7 | |a 5S6W795CQM |2 NLM | |
| 650 | 7 | |a Analgesics, Opioid |2 NLM | |
| 650 | 7 | |a Narcotic Antagonists |2 NLM | |
| 700 | 1 | |a Noss, Bryant |e verfasserin |4 aut | |
| 700 | 1 | |a Truong, Gia Thinh D |e verfasserin |4 aut | |
| 700 | 1 | |a Creech, Zachary A |e verfasserin |4 aut | |
| 700 | 1 | |a Koushik, Sarang S |e verfasserin |4 aut | |
| 700 | 1 | |a Urits, Ivan |e verfasserin |4 aut | |
| 700 | 1 | |a Viswanath, Omar |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t CNS drugs |d 1994 |g 37(2023), 8 vom: 28. Aug., Seite 663-670 |w (DE-627)NLM09374627X |x 1179-1934 |7 nnns |
| 773 | 1 | 8 | |g volume:37 |g year:2023 |g number:8 |g day:28 |g month:08 |g pages:663-670 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1007/s40263-023-01018-3 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 37 |j 2023 |e 8 |b 28 |c 08 |h 663-670 | ||